A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
GlioblastomaGliosarcomaAnaplastic Astrocytoma
Interventions
DRUG

PD 0332991 (pre-surgery)

PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression

DRUG

PD 0332991

PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles

PROCEDURE

Resection as clinical care

Indicated, intended, surgical resection as clinical care

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of California, San Francisco

OTHER